help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esteva, F. J.
Right arrow Articles by Hortobagyi, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esteva, F. J.
Right arrow Articles by Hortobagyi, G. N.
The Oncologist, Vol. 6, No. 2, 133-146, April 2001
© 2001 AlphaMed Press

Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond

Francisco J. Esteva, Vicente Valero, Lajos Pusztai, Laura Boehnke-Michaud, Aman U. Buzdar, Gabriel N. Hortobagyi

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Francisco J. Esteva, M.D., Assistant Professor of Medicine, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 56, Houston, Texas 77030, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: festeva{at}mdanderson.org

Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and the taxanes (paclitaxel, docetaxel) are considered the most active agents for patients with advanced breast cancer. Traditionally, the anthracyclines have been used in combination with cyclophosphamide and 5-fluorouracil (FAC, FEC). The taxanes have single-agent activity similar to older combination chemotherapy treatments. There is great interest in developing anthracycline/taxane combinations. Capecitabine is indicated for patients who progress after anthracycline and taxane therapy. Vinorelbine and gemcitabine have activity in patients with metastatic breast cancer and are commonly used as third- and fourth-line palliative therapy. The role of high-dose chemotherapy is not well-defined and remains experimental. Novel cytotoxic therapy strategies include the development of anthracycline, taxane, and oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, and multidrug resistance inhibitors.

A better understanding of the biology of breast cancer is providing novel treatment approaches. Oncogenes and tumor-supressor genes are emerging as important targets for therapy. Trastuzumab, a monoclonal antibody directed against the Her-2/neu protein, has been shown to prolong survival in patients with metastatic breast cancer. Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer.

Key Words. Breast neoplasm • Chemotherapy • Biologic therapy • Prognostic markers




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. M. Galmarini, I. Treilleux, F. Cardoso, C. Bernard-Marty, V. Durbecq, D. Gancberg, M.-C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart, et al.
Class III {beta}-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
Clin. Cancer Res., July 15, 2008; 14(14): 4511 - 4516.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. J. Esteva and G. N. Hortobagyi
Can Early Response Assessment Guide Neoadjuvant Chemotherapy in Early-Stage Breast Cancer?
J Natl Cancer Inst, April 16, 2008; 100(8): 521 - 523.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. C. Fields, D. B. Jeffe, K. Trinkaus, Q. Zhang, C. Arthur, R. Aft, J. R. Dietz, T. J. Eberlein, W. E. Gillanders, and J. A. Margenthaler
Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis
Ann. Surg. Oncol., December 1, 2007; 14(12): 3345 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. Gnerlich, D. B. Jeffe, A. D. Deshpande, C. Beers, C. Zander, and J. A. Margenthaler
Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988 2003 SEER Data
Ann. Surg. Oncol., August 1, 2007; 14(8): 2187 - 2194.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Cortes and J. Baselga
Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones
Oncologist, March 1, 2007; 12(3): 271 - 280.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Saeki, T. Nomizu, M. Toi, Y. Ito, S. Noguchi, T. Kobayashi, T. Asaga, H. Minami, N. Yamamoto, K. Aogi, et al.
Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer
J. Clin. Oncol., February 1, 2007; 25(4): 411 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. Soto-Cerrato, F. Vinals, J. R. Lambert, J. A. Kelly, and R. Perez-Tomas
Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3{beta} activity in human breast cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 362 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thurlimann, D. Hess, R. Graffeo, M. Ruggeri, et al.
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Ann. Onc., October 1, 2005; 16(10): 1609 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Huang, M. Bennett, and P. E. Thorpe
A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice
Cancer Res., May 15, 2005; 65(10): 4408 - 4416.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Alexopoulos, M. V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta, and G. Rigatos
Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer
Ann. Onc., June 1, 2004; 15(6): 891 - 895.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. C. Yocum, et al.
Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Burger, J. A. Foekens, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, E. A. C. Wiemer, G. Stoter, and K. Nooter
RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response
Clin. Cancer Res., February 1, 2003; 9(2): 827 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. V. Desai, N. Xiao, W. Wang, L. Gangi, J. Greene, J. I. Powell, R. Dickson, P. Furth, K. Hunter, R. Kucherlapati, et al.
Initiating oncogenic event determines gene-expression patterns of human breast cancer models
PNAS, May 14, 2002; 99(10): 6967 - 6972.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.